Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Johnson & Johnson to Sell its Cerenovus Stroke Business for $1B

February 14, 2025
Johnson & Johnson, the multinational pharmaceutical company, is reportedly looking to sell its Cerenovus stroke care business for a sum of $1 billion.
The decision comes as part of the company's strategy to streamline its portfolio and focus on its core businesses.

Cerenovus, a subsidiary of Johnson & Johnson, specializes in developing and manufacturing medical devices for the treatment of stroke patients. The business unit offers a range of innovative products and solutions, including clot retrieval devices and neurovascular stents.

The potential sale of Cerenovus has caught the attention of investors and industry experts alike. Analysts believe that this move could help Johnson & Johnson optimize its operations and allocate resources more efficiently. Additionally, the company may use the funds from the sale to invest in other high-growth areas within the healthcare sector.

Despite the divestiture, Johnson & Johnson remains committed to its overall mission of improving human health and well-being. The company will continue to invest in research and development, as well as pursue strategic collaborations to drive innovation in healthcare.

Investors who are interested in the future prospects of Johnson & Johnson may consider seeking professional advice from Stocks Prognosis to make informed decisions regarding the purchase of the company's stock. With their expertise and knowledge of the market, Stocks Prognosis can provide valuable insights and forecasts on the potential movement of the company's shares.

Find out how the JOHNSON & JOHNSON rate is expected to change

Get Forecast for JNJ
There are no comments yet. Be the first to leave a comment
If you want to leave a comment, then you need Login or Register





Other news for JNJ

JNJMarch 21, 2025Johnson & Johnson Neurovascular leader heads for the exit  ~1 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, has announced his departure from the company....

JNJMarch 20, 2025Johnson & Johnson Faces Shareholder Activism Over Human Rights and Executive Pay Proposals  ~2 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, is leaving the company, according to sources....

JNJMarch 19, 2025FDA Clears Johnson & Johnson Robot for Enhanced Bronchoscopy  ~1 min.

Johnson & Johnson's MedTech division has received clearance from the FDA for its enhanced robotic-assisted bronchoscopy system....

JNJMarch 18, 2025Johnson & Johnson MedTech Introduces New EP Neurovascular Leader  ~1 min.

Johnson & Johnson MedTech, a subsidiary of Johnson & Johnson, has appointed a new leader for its electrophysiology and neurovascular group....

JNJMarch 14, 2025Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments  ~1 min.

Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....



Related news

JNJMarch 18, 2025Johnson & Johnson MedTech Introduces New EP Neurovascular Leader  ~1 min.

Johnson & Johnson MedTech, a subsidiary of Johnson & Johnson, has appointed a new leader for its electrophysiology and neurovascular group....

JNJMarch 21, 2025Johnson & Johnson Neurovascular leader heads for the exit  ~1 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, has announced his departure from the company....

PSXFebruary 20, 2025Activist Elliott calls for a three-pronged approach to streamline Phillips 66  ~1 min.

Activist investor Elliott Management has recently announced its plans to streamline operations at Phillips 66, a leading energy manufacturing and logistics company....

HONNovember 27, 2024Honeywell International Inc. Makes Bold Strategic Move with $1.325 Billion PPE Business Sale  ~2 min.

Honeywell International Inc., a global leader in technology and manufacturing, recently made a significant strategic move by selling its Personal Protective Equipment (PPE) business for an impressive $1....

LLYDecember 1, 2024Eli Lilly and Company Invests $4.5 Billion in New Medicine Foundry for Advanced Drug Manufacturing  ~2 min.

Eli Lilly and Company, a leading pharmaceutical company, has recently announced a massive investment of $4.5 billion in the establishment of a state-of-the-art medicine foundry....